PANCAID PANcreatic CAncer Initial Detection via liquid biopsy
- Coordinator
- Universitaetsklinikum Hamburg-Eppendorf, Germany
- Runs
- 1 January 2023 to 31 December 2027
- Status
- Running
- EU funding
- €9.8m
- Total cost
- €9.8m
- Partners
- 22 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101096309
What the project is doing
In the project's own words, from its summary on CORDIS.
Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g., DNA, RNA, protein, metabolites) into the circulation.
Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population).
Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5).
A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals.
This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitaetsklinikum Hamburg-Eppendorf | Hamburg | Germany | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| Pancreatic Cancer Europe | Bruxelles / Brussel | Belgium | Participant |
| Christian-Albrechts-Universitaet Zu Kiel | Kiel | Germany | Third party |
| Concentris Research Management GmbH | Furstenfeldbruck | Germany | Participant |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| Universitatsklinikum Schleswig-Holstein | Lübeck | Germany | Participant |
| Zava Deutschland GmbH | Hamburg | Germany | Participant |
| Zava Global GmbH | Hamburg | Germany | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal | Madrid | Spain | Participant |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii | Madrid | Spain | Participant |
| Centre Hospitalier Universitaire Montpellier | Montpellier | France | Participant |
| Maccabi Sheirutei Briut Foundation | Tel Aviv | Israel | Participant |
| The Hebrew University of Jerusalem | Jerusalem | Israel | Participant |
| Collective Minds Radiology AB | Danderyd | Sweden | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Umea Universitet | Umea | Sweden | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| Queen Mary University of London | London | United Kingdom | Associatedpartner |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI